Emily K. Bergsland, MD

University of Wisconsin, B.S., 1985, Biochemistry and Molecular Biology
University of Minnesota, M.D., 1982

• 1989-92
  Intern, Dept. of Medicine, University of California San Francisco
• 1990-92
  Resident, Dept. of Medicine, University of California San Francisco
• 1992-92
  Chief Resident and Assistant Chief of the Medical Service, Dept. of Medicine, University of California San Francisco
• 1993-92
  Fellow, Medical Oncology, University of California San Francisco
• 1994-1992
  Research Fellow (P I: Douglas Hanahan, Ph.D.), Department of Biochemistry and Biophysics, University of California San Francisco
• Transgenic mouse models of tumorigenesis
• 1996-1992
  Clinical Instructor, Dept. of Medicine (Division of Hematology/Oncology), UCSF
• 1998-2002
  Assistant Clinical Professor, Dept of Medicine (Division of Hematology/Oncology), UCSF
• 2003-2002
  Associate Director, Hematology/Oncology Fellowship Program, UCSF
• 2004-present
  Associate Professor, Dept. of Medicine, Division of Hematology/Oncology, UCSF
• 2006-present
  Director of Education and Fellowship Program Director, Hematology/Oncology

• 1982
  Phi Beta Kappa
• 1985-82
  Vine Scholarship, University of Minnesota
• 1982
  May Sine Peterson Award, University of Minnesota
• 1982
  Alpha Omega Alpha
• 1995-92
  Molecular Medicine Fellowship, University of California San Francisco

• Bullard KM, Banda MJ, Arbeit JM, Bergsland EK, Young DM. Human Acellular Dermal Matrix as a Novel Model of Malignant Epithelial Cell Invasion. Invasion and Metastasis. 1997; 17: 42-52.
• Hanahan D, Bergers G, & Bergsland E. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. Journal of Clinical Investigation. 2000: 105: 1045-1047.
• Kabbinavar F, Hurwitz H, Fehrenbacher L., Meropol L, Novotny W, Gaudreault J, Lieberman G, Bergsland E. A Randomized Phase II Trial comparing rhuMAb VEGF Plus 5-Fluorouracil/Leucovorin (FU/LV) to Chemotherapy Alone in Patients with Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2003; 21: 60-65.
• Ko A, Bergsland E, & Lee G. Tumorassociated hypoglycemia from metastatic colorectal adenocarcinoma: Case report and review of the literature. Digestive Diseases and Sciences 48; 192-196, 2003.
• Daniel D, Meyer-Morse N, Bergsland E, Dehne K, Coussens L, Hanahan D. Immune Enhancement of Squamous Epithelial Carcinogenesis by CD4+ T cells. Journal of Experimental Medicine 197; 1017-1028, 2003.
• Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with tyrosine kinase inhibitors. Journal of Clinical Investigation 111; 1287-95, 2003.
• Mohr D, Moran P, Kohn C, Hart S, Armstrong K, Dias R, Bergsland E Folkman S. Couples therapy at end of life. Psycho-Oncology 12: 620-627, 2003.
• Mehta K, Nakao K, Zuraek M, Ruan D, Bergsland E, Venook A, Fridlyand J, Moore D, Jain A, Warren R, Terdiman J, Waldman F. Fractional genomic alteration detected by array-based comparative genomic hybridization predicts survival after hepatic resection for metastatic colorectal cancer. Clinical Cancer Research, 2005;11: 1791-7.
• Kabbinavar F. Hambleton J, Mass R, Hurwitz H, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. Journal of Clinical Oncology, 2005;23: 3706-12.
• Ko, A., Hwang J, Venook A, Abbruzzese JL, Bergsland E, Tempero M. Using serum CA 19-9 response as a surrogate for clinical outcome in patients with advanced pancreatic cancer treated with fixed-dose rate gemcitabine. Br J Cancer, 2005; 93: 195-9.
• Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol. 2006 ;24(3):379-85.
• Rajpal S, Warren R, Alexander M, Yeh B, Grenert J, Hintzen S, Ljung, BM, Bergsland E. Pancreatoblastoma in an adult. Journal of Gastrointestinal Surgery. 2006, Jun;10(6):829-36.
• Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, Michelini A, Kinsella K, Venook AP, Fuchs CS. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol. 2006, Aug 1;24(22):3555-61.